Cold War tensions and the polio vaccine Sabin vaccine from the Soviet side. However other Soviet virologists argued that the Salk vaccine could be considered safe, since the Americans tested it on their own people. They considered that the Sabin vaccine must be potentially dangerous because the Americans did not wish to test it on their own society. The documented achievement of the Sabin-Chumakov collaboration eventually trumped the ideological differences of the Cold War. Their oral live-virus vaccine became federally licensed in 1962, and used for over three decades to help eliminate polio globally, replacing the Salk vaccine. Using these vaccines, the threat of polio remains only
Remune P < 0.05 & HIV-1 lymphocyte proliferation P < 0.001 both favoring the Remune Group. The International AIDS Vaccine Research (IAVA) issued a report on “Whole Killed AIDS Vaccines” in 1999 reviewing a diverse aspect of the killed virus approach. Remune Remune is the first therapeutic HIV vaccine based on the killed whole virus approach. Remune was initially invented by Jonas Salk in 1987 and is now being developed by Immune Response BioPharma, Inc. (IRBP) Remune is a therapeutic HIV/AIDS vaccine that has completed over 25 clinical studies to date and shows a robust mechanism of action restoring white blood